Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04523909

Trajectory of Neuroinflammatory Markers in Cerebrospinal Fluid Prior to and After Thoracic Aortic Surgery

Observational prospective pilot study to analyze the trajectory of neuroinflammatory protein expression in cerebrospinal fluid (CSF) in relation to systemic compartment in patients undergoing thoracic aortic surgery.

The aim of this study is to identify and unravel the biochemical (neuroinflammatory) pathways involved in postoperative delirium.

Patient undergoing thoracic aortic surgery will have an external lumbar drain (ELD) in situ on the day before surgery. This ELD remains in place during and three days after surgery to reduce the risk on periprocedural spinal cord ischemia. Paired measurements of CSF and blood will be analyzed.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Major (cardiovascular) surgery is frequently associated with cerebral dysfunction postoperatively. Major surgical procedures account for substantial systemic inflammatory activation. Interestingly, animal models have shown that surgery rather than anaesthetics trigger a neurocognitive decline. An increase of pro-inflammatory cytokines and activation of immune cells mediate this post operative cognitive decline. There is growing support that systemic inflammation can activate the innate immune system of the brain leading to inflammation in the brain ('neuroinflammation'). This neuroinflammation is suggested to play a pivotal role in postoperative delirium and postoperative cognitive decline due to surgery-related systemic inflammation. However little evidence is available on the extend of the neuroinflammation and which biochemical pathways are dysregulated in the brain after surgery.

Thoracic aortic surgery offers the unique opportunity to study the trajectory of protein expression in CSF prior to and after surgery in a non-invasive matter. It is standard of care that an external lumbar drain (ELD) is placed the day prior to surgery and this ELD will remain in place during three postoperative days.

To advance the understanding of the impact of major surgery to the brain, the investigators wish to study the trajectory of protein expression prior to and after thoracic aortic surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Competent patients ≥ 18 years
  • Patients who will undergo thoracic aortic surgery and will therefore receive an external lumbar drain as a standard of care procedure.

Exclusion criteria

  • Patients with meningitis/encephalitis/brain abscess within the last 6 months
  • Patients with other neurological conditions: brain injury (acute stroke, brain trauma or cerebral haemorrhage) within the last 3 months, known brain tumours, neurodegenerative disease or known pre-existing cognitive impairment (to a degree that would be compatible with mild cognitive impairment or more).
  • Brain or spinal surgery within the last 3 months
  • Active infection <2 weeks before surgery
  • Patients who object against storage of their body material for scientific reasons

Treatment and study plan

Trajectory of neuroinflammatory proteins in CSF and blood

Diagnostic Test

Kinetics of neuroinflammatory markers in CSF and blood

Primary outcomes

  1. Trajectory of the concentration of a panel of inflammatory proteins in CSF

    Time frame: 9 timepoints: Baseline (immediately before surgery); Start extracorporeal circulation; Stop extracorporeal circulation (ECC); 2 hours (h) after stop ECC; 4h after stop ECC; 6h after stop ECC; 24h after baseline; 48h after baseline; 72h after baseline

    Changes in CSF cytokine concentrations will be determined (including IL6, IL8, IL10, MCP-1, IL1RA and CX3CL1) between timepoints described below.

Secondary outcomes

  1. Trajectory of the concentration of a panel of inflammatory proteins in plasma

    Time frame: 9 timepoints: Baseline to 72 hours after surgery

    Changes in plasma cytokine concentrations will be determined (including IL6, IL8, IL10, MCP-1, IL1RA and CX3CL1) between timepoints described below.

  2. Trajectory of blood-CSF barrier disruption based on CSF/Plasma albumine ratio

    Time frame: 9 timepoints: Baseline to 72 hours after surgery

    CSF/Plasma albumine ratios will be measured for all timepoints where paired CSF/plasma samples are present

  3. Occurence of postoperative delirium

    Time frame: 14-day incidence of delirium

    Yes or No

  4. Trajectory of brain injury markers in CSF

    Time frame: 9 timepoints: Baseline to 72 hours after surgery

    Changes in brain injury markers will be determined (including NFL, S100B, GFAP, UCHL1, NSE)

  5. Trajectory of brain injury markers in plasma

    Time frame: 9 timepoints: Baseline to 72 hours after surgery

    Changes in brain injury markers will be determined (including S100B, GFAP, UCHL1, NSE)

  6. Changes in ex vivo cytokine production after whole blood stimulation

    Time frame: 5 timepoints: Baseline to 48 hours after surgery

    TNF-a,IL6, IL10

  7. Changes in mHLA-DR expression

    Time frame: 5 timepoints: Baseline to 48 hours after surgery

    monocytic HLA-DR expression assessed by flowcytometry

Study contacts

Contact information is provided by the study sponsor or research team.

Wilson F. Abdo, MD, PhD

CONTACT

[email protected]

+31243617273

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Registry information

Official study title

Trajectory of Neuroinflammatory Markers in Cerebrospinal Fluid Prior to and After Thoracic Aortic Surgery: the TURBO Study

Acronym: TURBO

Important dates

Study start
2017
Primary completion
2025
Study completion
2026
First posted
Aug 24, 2020
Registry last updated
Mar 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.